| A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia (NCT07225712) | Otsuka Pharmaceutical Co., Ltd. | 2025-12-22 |
| A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis (NCT07173478) | Otsuka Pharmaceutical Co., Ltd. | 2025-10-01 |
| LUPKYNIS Drug-use Results Survey (NCT07053891) | Otsuka Pharmaceutical Co., Ltd. | 2025-09-17 |
| A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD (NCT07086313) | Otsuka Pharmaceutical Co., Ltd. | 2025-09-03 |
| A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis (NCT07184645) | Otsuka Pharmaceutical Co., Ltd. | 2025-09-01 |
| A Long-term Trial of EB-1020 in Adult Patients With ADHD (NCT06926829) | Otsuka Pharmaceutical Co., Ltd. | 2025-06-25 |
| REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease) (NCT06875986) | Otsuka Pharmaceutical Co., Ltd. | 2025-04-17 |
| Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia (NCT06036108) | Otsuka Pharmaceutical Co., Ltd. | 2023-10-03 |
| Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure. (NCT05712746) | Otsuka Pharmaceutical Co., Ltd. | 2023-03-03 |
| A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia (NCT05687071) | Otsuka Pharmaceutical Co., Ltd. | 2023-02-27 |
| A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia (NCT05683340) | Otsuka Pharmaceutical Co., Ltd. | 2023-02-13 |
| A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF]) (NCT05615363) | Otsuka Pharmaceutical Co., Ltd. | 2023-01-10 |
| Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia (NCT05325645) | Otsuka Pharmaceutical Co., Ltd. | 2022-07-21 |
| A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia (NCT05326347) | Otsuka Pharmaceutical Co., Ltd. | 2022-05-31 |
| Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use (NCT05342493) | Otsuka Pharmaceutical Co., Ltd. | 2022-04-20 |
| A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia (NCT05119894) | Otsuka Pharmaceutical Co., Ltd. | 2021-11-22 |
| Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP) (NCT04812379) | Otsuka Pharmaceutical Co., Ltd. | 2021-04-07 |
| Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH (NCT04790175) | Otsuka Pharmaceutical Co., Ltd. | 2021-03-29 |
| A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia (NCT04784442) | Otsuka Pharmaceutical Co., Ltd. | 2021-03-24 |
| Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT04649073) | Otsuka Pharmaceutical Co., Ltd. | 2021-02-18 |
| A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma (NCT04362007) | Otsuka Pharmaceutical Co., Ltd. | 2020-07-14 |
| A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients (NCT04355117) | Otsuka Pharmaceutical Co., Ltd. | 2020-06-17 |
| A Phase 2 Trial of OPC-64005 for Major Depressive Disorder (NCT04244253) | Otsuka Pharmaceutical Co., Ltd. | 2020-03-03 |
| A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects (NCT04182958) | Otsuka Pharmaceutical Co., Ltd. | 2019-11-25 |
| A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL (NCT04049825) | Otsuka Pharmaceutical Co., Ltd. | 2019-11-22 |
| A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses (NCT04118127) | Otsuka Pharmaceutical Co., Ltd. | 2019-10-17 |
| Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence (NCT04107051) | Otsuka Pharmaceutical Co., Ltd. | 2019-10-01 |
| Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake (NCT03962101) | Otsuka Pharmaceutical Co., Ltd. | 2019-06-17 |
| Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis (NCT03961529) | Otsuka Pharmaceutical Co., Ltd. | 2019-05-14 |
| Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis (NCT03911401) | Otsuka Pharmaceutical Co., Ltd. | 2019-05-07 |
| Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg (NCT03902574) | Otsuka Pharmaceutical Co., Ltd. | 2019-03-27 |
| Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome (NCT03908970) | Otsuka Pharmaceutical Co., Ltd. | 2019-03-25 |
| Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes (NCT03906695) | Otsuka Pharmaceutical Co., Ltd. | 2019-03-15 |
| Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure (NCT03772041) | Otsuka Pharmaceutical Co., Ltd. | 2019-01-16 |
| Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type (NCT03724942) | Otsuka Pharmaceutical Co., Ltd. | 2018-11-09 |
| A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder (NCT03737474) | Otsuka Pharmaceutical Co., Ltd. | 2018-10-04 |
| Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type (NCT03620981) | Otsuka Pharmaceutical Co., Ltd. | 2018-08-20 |
| A Study of Brexpiprazole in Patients With Major Depressive Disorder (NCT03697603) | Otsuka Pharmaceutical Co., Ltd. | 2018-07-30 |
| Phase I Study of OPC-61815 (NCT03510663) | Otsuka Pharmaceutical Co., Ltd. | 2018-05-08 |
| Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload (NCT03255226) | Otsuka Pharmaceutical Co., Ltd. | 2018-03-07 |
| Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine (NCT03303079) | Otsuka Pharmaceutical Co., Ltd. | 2017-12-19 |
| Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine (NCT03303092) | Otsuka Pharmaceutical Co., Ltd. | 2017-12-19 |
| Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine (NCT03303105) | Otsuka Pharmaceutical Co., Ltd. | 2017-12-07 |
| Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure (NCT03254108) | Otsuka Pharmaceutical Co., Ltd. | 2017-11-06 |
| A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients (NCT03284177) | Otsuka Pharmaceutical Co., Ltd. | 2017-10-31 |